Agenus is an immuno-oncology company with a long history and a broad portfolio. To help fund its pipeline, it entered into a significant alliance with Gilead Sciences in December 2018 and has used an unusual funding mechanism by raising money through what it described as the first asset-backed digital-security offering. We spoke to John Castle, head of translational medicine and bioinformatics at Agenus, about the company’s approach to managing and prioritizing its pipeline, its use of artificial intelligence, and the recent deals it’’s done to fund development.